Morphic Holding Inc Quick Ratio (MORF) starting from the second quarter 2024 to second quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Morphic Holding inc   (NASDAQ: MORF)

Morphic Holding Inc 's Quick Ratio

MORF's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2024, Quick Ratio fell to 23.71 below Morphic Holding Inc average.

Within Major Pharmaceutical Preparations industry Morphic Holding inc booked the highest Quick Ratio than Morphic Holding Inc in the second quarter 2024. While Quick Ratio total ranking in the second quarter 2024 has deteriorated compared to the prior quarter from 4 to 8.

Explain Quick Ratio?
How much Cash & cash equivalents MORF´s has?
What are MORF´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MORF Quick Ratio (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2
Y / Y Current Liabilities Change 48.83 % 31.38 % 48.75 % 26.62 % 16.92 %
Y / Y Cash & cash equivalent Change -14.08 % 56.37 % 102.26 % 95.04 % 83.96 %
Quick Ratio MRQ 23.71 37.2 28.43 37.57 41.07
MORF's Total Ranking # 8 # 4 # 20 # 53 # 65
Seq. Current Liabilities Change 49.65 % -28.52 % 28.39 % 8.36 % 32.1 %
Seq. Cash & cash equivalent Change -4.61 % -6.47 % -2.86 % -0.86 % 73.6 %



Quick Ratio second quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 0
Healthcare Sector # 0
Overall Market # 8


Quick Ratio Statistics
High Average Low
41.07 25.55 10.24
(Jun 30 2023)   (Sep 30 2021)




Financial Statements
Morphic Holding Inc 's Current Liabilities $ 27 Millions Visit MORF's Balance sheet
Morphic Holding Inc 's Cash & cash equivalent $ 628 Millions Visit MORF's Balance sheet
Source of MORF's Sales Visit MORF's Sales by Geography


Cumulative Morphic Holding Inc 's Quick Ratio

MORF's Quick Ratio for the trailling 12 Months

MORF Quick Ratio

 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 39.73 % 31.32 % 24.34 % 9.17 % -28.29 %
Y / Y Cash & cash equivalent TTM Growth 45.06 % 83.22 % 72.34 % 42.86 % 16.03 %
Quick Ratio TTM 30.77 35.42 34.26 33.1 29.64
Total Ranking TTM # 2586 # 11 # 1553 # 2283 # 2349
Seq. Current Liabilities TTM Growth 10.93 % 5.61 % 12.08 % 6.42 % 4.25 %
Seq. Cash & cash equivalent TTM Growth -3.65 % 9.2 % 16 % 18.87 % 21.69 %

Quick ratio ranking by company, industry and sector >> Back to MORF Financial Strength Comparisons >> Go to Compare MORF Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2024 to $26.51 millions, cumulative Quick Ratio decreased to 30.77 above the MORF average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Morphic Holding Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2024 from 11 to 2586.

Explain Quick Ratio?
How much Cash & cash equivalents MORF´s has?
What are MORF´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 848
Within the Market # 2586


trailing twelve months Quick Ratio Statistics
High Average Low
35.42 22.26 10.38
(Mar 31 2024)   (Mar 31 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2024 MRQ Cash & cash equivalentJun 30 2024 MRQ Current Liabilities
Context Therapeutics Inc   63.29 $ 101.537  Millions$ 1.604  Millions
Altimmune inc   61.35 $ 164.908  Millions$ 2.688  Millions
Climb Bio Inc   59.65 $ 223.140  Millions$ 3.741  Millions
Onkure Therapeutics Inc   56.88 $ 76.674  Millions$ 1.348  Millions
Janux Therapeutics Inc   55.98 $ 646.293  Millions$ 11.545  Millions
Tao Synergies Inc   52.43 $ 27.414  Millions$ 0.523  Millions
Moonlake Immunotherapeutics  42.32 $ 519.800  Millions$ 12.282  Millions
Rapport Therapeutics Inc   41.52 $ 336.139  Millions$ 8.095  Millions
Structure Therapeutics Inc   40.92 $ 927.119  Millions$ 22.659  Millions
Oramed Pharmaceuticals Inc  40.92 $ 152.737  Millions$ 3.733  Millions
Design Therapeutics Inc   40.82 $ 261.016  Millions$ 6.394  Millions
Third Harmonic Bio Inc   40.20 $ 255.331  Millions$ 6.352  Millions
Viking Therapeutics Inc   38.06 $ 942.263  Millions$ 24.759  Millions
Tyra Biosciences Inc   36.00 $ 373.796  Millions$ 10.382  Millions
Dianthus Therapeutics Inc   35.97 $ 360.707  Millions$ 10.029  Millions
Ars Pharmaceuticals Inc   33.32 $ 218.744  Millions$ 6.565  Millions
Ionis Pharmaceuticals Inc   31.03 $ 5,221.001  Millions$ 168.279  Millions
Sagimet Biosciences inc   29.84 $ 166.373  Millions$ 5.575  Millions
Edgewise Therapeutics inc   29.79 $ 511.751  Millions$ 17.176  Millions
Immunome Inc   29.61 $ 278.353  Millions$ 9.400  Millions
Aprea Therapeutics Inc   28.27 $ 28.695  Millions$ 1.015  Millions
Roivant Sciences Ltd   26.41 $ 5,678.514  Millions$ 215.045  Millions
Arca Biopharma Inc  26.19 $ 33.283  Millions$ 1.271  Millions
Dyne Therapeutics Inc   26.18 $ 778.838  Millions$ 29.753  Millions
Jade Biosciences Inc   25.93 $ 177.440  Millions$ 6.842  Millions
Arrivent Biopharma inc   24.69 $ 298.669  Millions$ 12.098  Millions
Disc Medicine Inc   24.66 $ 500.945  Millions$ 20.310  Millions
Akero Therapeutics Inc   24.39 $ 760.194  Millions$ 31.174  Millions
Atrium Therapeutics Inc   24.20 $ 1,300.589  Millions$ 53.750  Millions
Morphic Holding inc   23.71 $ 628.366  Millions$ 26.505  Millions

Date modified: 2026-09-08T19:02:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.